Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018

  • ID: 4583877
  • Report
  • 853 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Boston Biomedical Inc
  • Eli Lilly and Co
  • Innopharmax Inc
  • NanoCarrier Co Ltd
  • Plexxikon Inc
  • MORE
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

Report Highlights:

This latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 63, 30, 16 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 4 molecules, respectively.

Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Boston Biomedical Inc
  • Eli Lilly and Co
  • Innopharmax Inc
  • NanoCarrier Co Ltd
  • Plexxikon Inc
  • MORE
Introduction

Bile Duct Cancer (Cholangiocarcinoma) - Overview

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment

Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development

Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products

Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AbbVie Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Advenchen Laboratories LLC, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca Plc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corp, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celldex Therapeutics Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellestia Biotech AG, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CytomX Therapeutics Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Debiopharm International SA, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eddingpharm Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Co, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Fujifilm Holdings Corporation, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Genentech Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Genoscience Pharma, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by H3 Biomedicine Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Hutchison MediPharma Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Immunitor Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Incyte Corp, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ipsen SA, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Leap Therapeutics Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Lexicon Pharmaceuticals Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co Ltd, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MediciNova Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune LLC, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co Inc, H1 2018

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Molecular Templates Inc, H1 2018

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4SC AG
  • AbbVie Inc
  • Advenchen Laboratories LLC
  • Agios Pharmaceuticals Inc
  • Ariad Pharmaceuticals Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Aslan Pharmaceuticals Pte Ltd
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellestia Biotech AG
  • Cellular Biomedicine Group Inc
  • CytomX Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Delcath Systems Inc
  • Eddingpharm Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • Genentech Inc
  • Genoscience Pharma
  • H3 Biomedicine Inc
  • Halozyme Therapeutics Inc
  • Hutchison MediPharma Ltd
  • Immunitor Inc
  • Incyte Corp
  • Innopharmax Inc
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Komipharm International Co Ltd
  • Leap Therapeutics Inc
  • Lexicon Pharmaceuticals Inc
  • Loxo Oncology Inc
  • Mebiopharm Co Ltd
  • MediciNova Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Molecular Templates Inc
  • NanoCarrier Co Ltd
  • NormOxys Inc
  • Novartis AG
  • NuCana Plc
  • Oasmia Pharmaceutical AB
  • OncoTherapy Science Inc
  • Ono Pharmaceutical Co Ltd
  • PCI Biotech Holding ASA
  • Pfizer Inc
  • Pharma Mar SA
  • Plexxikon Inc
  • Provecs Medical GmbH
  • Puma Biotechnology Inc
  • Rafael Pharmaceuticals Inc
  • RedHill Biopharma Ltd
  • Sanofi
  • Senhwa Biosciences Inc
  • Sensei Biotherapeutics Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sirnaomics Inc
  • Sun Pharma Advanced Research Company Ltd
  • SynCore Biotechnology Co Ltd
  • Syndax Pharmaceuticals Inc
  • SyntheX Inc
  • Taiho Pharmaceutical Co Ltd
  • Taris Biomedical LLC
  • TCR2 Therapeutics Inc
  • tella Inc
  • Tesaro Inc
  • VasGene Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll